{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.08","upperLimit":"10.48","value":"7.03"},{"groupId":"OG001","lowerLimit":"1.18","upperLimit":"4.86","value":"2.10"},{"groupId":"OG002","lowerLimit":"1.38","upperLimit":"1.84","value":"1.51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"PFS was defined as the length of time from the first dose of study drug (Day 1) to the earlier of death or disease progression by RECIST v1.1, as assessed by the independent centralized radiological review committee.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with fibroblast growth factor (FGF) receptor 2 (FGFR2) rearrangements or fusions self-administered oral pemigatinib at a starting dose of 13.5 milligrams (mg) once daily (QD) on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG000","title":"Cohort A: FGFR2 Rearrangements or Fusions"},{"description":"Participants with all other FGF/FGFR alterations self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG001","title":"Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions"},{"description":"Participants with no FGF/FGFR alterations self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles (United States only). Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG002","title":"Cohort C: Negative for FGF/FGFR Alterations"},{"description":"Participants with an FGF/FGFR status for whom the local laboratory FGF/FGFR results could not be confirmed centrally self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG003","title":"Other"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Population. Two participants were assigned to a group labeled \"Other\" and were excluded from the EEP because the local laboratory FGF/FGFR results could not be confirmed centrally. The 95% confidence intervals were calculated using the Brookmeyer and Crowley's method.","reportingStatus":"POSTED","timeFrame":"up to 50.17 months","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}